Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis

Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded company in the HEALTHCARE sector. It trades at $15.39, carries a market capitalization of $1.97B, a price-to-earnings ratio of 7.09. This page summarizes the public market data, fundamentals, and frequently asked questions for AUPH, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.39
• Market Cap: $1.97B
• P/E Ratio: 7.09
• EPS: $2.16
• 52-Week High: $16.88
• 52-Week Low: $7.29

Market Sentiment

Aurinia Pharmaceuticals Inc currently has a Bullish sentiment score of 0.18.

GNG Research Analysis

GNG Research scores Aurinia Pharmaceuticals Inc (AUPH) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for AUPH.

Frequently Asked Questions

Does AUPH pay dividends?

Aurinia Pharmaceuticals Inc (AUPH) does not currently pay a regular dividend.

What is AUPH's P/E ratio?

Aurinia Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 7.09.

What is AUPH's market cap?

Aurinia Pharmaceuticals Inc (AUPH) has a market capitalization of $1.97B with a current stock price of $15.39.